Skip to content
Triangle logo TriangleGet started
← Study library

NCT02408016 · REGISTRY CONDITION SEARCH

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
TERMINATED
Registry last update
2021-09-13

This phase I/II trial studies the side effects and best dose of genetically modified T cells in treating patients with stage III-IV non-small cell lung cancer (NSCLC) or mesothelioma. Many types of cancer cells, including NSCLC and mesothelioma, but not most normal cells, have a protein called Wilms tumor (WT)1 on their surfaces. This study takes a type of immune cell from patients, called T cells, and modifies their genes in the laboratory so that they are programmed to find cells with WT1 and kill them. The T cells are then given back to the patient. Cyclophosphamide and aldesleukin may also stimulate the immune system to attack cancer cells. Giving cyclophosphamide and aldesleukin with laboratory-treated T cells may help the body build an immune response to kill tumor cells.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Adverse Events

→

outcome · POSTED

Count of Patients for Which T Cells Are Successfully Generated and Infused and Whether Only TN or TCM Could be Generated

→

outcome · POSTED

Persistence of Transduced T Cells

→

outcome · NOT POSTED

Frequency of Transferred T Cells at Biopsied Tumor Sites Between the T Cell (Tn) and Memory T Cell (Tcm) Groups

→

outcome · NOT POSTED

Functional Capacity of Transferred Cells, Measured by Production of Intracellular Cytokines

→

outcome · NOT POSTED

Time to Progression (TTP) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria and RECIST 1.1 Mesothelioma Modified

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * ELIGIBILITY FOR ENROLLMENT/SCREENING (ARMS 1 AND 2): Histopathological documentation of NSCLC or mesothelioma * ELIGIBILITY FOR ENROLLMENT/SCREENING (ARMS 1 AND 2): Patients must be able to give informed consent * ELIGIBILITY FOR ENROLLMENT/SCREENING (ARMS 1 AND 2): Patients must be able to provide blood and tumor samples and undergo the procedures required for this protocol * Arm 2 ONLY: Surgically operable NSCLC or mesothelioma * ELIGIBILITY FOR TREATMENT ON ARM 1: Patients must express human leukocyte antigen (HLA)-A\*0201 * ELIGIBILITY FOR TREATMENT ON ARM 1: Evidence of WT1 tumor expression * ELIGIBILITY FOR TREATMENT ON ARM 1: Patients must have received at least one line of therapy for NSCLC or mesothelioma or previously documented to have declined therapy * ELIGIBILITY FOR TREATMENT ON ARM 1: NSCLC patients with a mutation in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) must have demonstrated progression or intolerance to at least one of the corresponding targeted therapies (for example erlotinib or crizotinib) * ELIGIBILITY FOR TREATMENT ON ARM 1: Bi-dimensionally measurable disease by palpation, clinical exam, or radiographic imaging (X-ray, computed tomography \[CT\] scan, positron emission tomography \[PET\] scan, magnetic resonance imaging \[MRI\], or ultrasound) * ELIGIBILITY FOR TREATMENT ON ARM 1: Ninety days must have passed since the last doses of radiation or chemoradiation treatment involving lung tissue or thorax prior to T cell infusion (to avoid confounding pneumonitis) * ELIGIBILITY FOR TREATMENT ON ARM 1: Patients treated with prior immunotherapy including and not limited to vaccines, cytokines, T cell stimulating agents, cytotoxic T lymphocyte antigen 4 (CTLA4) inhibitors and programmed death (PD)-1 check point inhibitors are allowed on therapy provided they did not have any severe grade 4 toxicities due to prior therapy and any toxicities due to prior therapy should have resolved, if resolvable to less than or equal to grade 1 * ELIGIBILITY FOR TREATMENT ON ARM 2: Patients must express HLA-A\*0201 * ELIGIBILITY FOR TREATMENT ON ARM 2: Evidence of WT1 tumor expression * ELIGIBILITY FOR TREATMENT ON ARM 2: Ninety days must have passed since the last definitive doses of radiation or chemoradiation treatment prior to T cell infusion (to avoid confounding pneumonitis) Exclusion Criteria: * EXCLUSION FOR ENROLLMENT/SCREENING (ARMS 1 AND 2) * Eastern Cooperative Oncology Group (ECOG) performance status \>= 2 * Active autoimmune disease (e.g., systemic lupus erythematosus, vasculitis, infiltrating lung disease, inflammatory bowel disease) in which possible progression during treatment would be considered unacceptable by the investigators * Any condition or organ toxicity deemed by the principal investigator (PI) or the attending physician to place the patient at unacceptable risk for treatment on the protocol * Men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative urine pregnancy test within 2 weeks prior to first infusion * Pregnant women and nursing mothers will be eligible for screening only to test HLA type by saliva or buccal swab and WT1 expression from previously collected tissue sample * Clinically significant and ongoing immune suppression including, but not limited to, systemic immunosuppressive agents such as cyclosporine or corticosteroids, chronic lymphocytic leukemia (CLL), uncontrolled human immunodeficiency virus (HIV) infection, or solid organ transplantation * EXCLUSION FOR TREATMENT (ARMS 1 AND 2) * Exclusions for the leukapheresis procedure (this can be performed at a later time of symptoms resolve): * Infection, with or without antibiotic treatment * Recent hepatitis exposure (hepatitis B or C antigenemia) * Pregnancy or nursing * HIV or human T-lymphotropic virus (HTLV) infection * Positive result on standard test for syphilis (STS) * Unable to generate antigen-specific WT1-specific CD8+ T cells for infusions; however, the patient will have the option to receive WT1-specific T-cells if a lower than planned number of cells is available * Documented infections or known oral temperature \> 38.2 degrees Celsius (C) fewer than 72 hours prior to receiving study treatment or systemic infection requiring chronic maintenance; the start of treatment may be delayed * Systemic steroids should be stopped 2 weeks before the start of treatment; topical and inhaled steroids are allowed * Untreated central nervous system (CNS) metastasis that are \> 1 cm or symptomatic are not allowed; (patients with CNS metastases \> 1 cm or symptomatic that have been treated and demonstrated to be radiologically and clinically stable for at least 4 weeks are allowed) * White blood cells (WBC) \< 2,000/ul * Hemoglobin (Hb) \< 8 g/dL * Absolute neutrophil count (ANC) \< 1,000/ul * Platelets \< 50,000/ul * New York Heart Association functional class III-IV heart failure, symptomatic pericardial effusion, stable or unstable angina, symptoms of coronary artery disease (CAD), congestive heart failure, clinically significant hypotension or history of an ejection fraction of =\< 30% (echocardiogram or multi-gated acquisition scan \[MUGA\]) * Clinically significant pulmonary dysfunction, as determined by medical history and physical exam; patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in 1 second (FEV1) \< 2.0 L or diffusion capacity of the lungs for carbon monoxide (DLCO) (corrected for Hb) \< 50% will be excluded * Creatinine \> 1.5 x the upper limit of normal * Aspartate aminotransferase/alanine aminotransferase (AST/ALT) \> 5 x upper limits of normal (ULN) * Bilirubin \> 3 x ULN that cannot be attributed to NSCLC metastasis * HIV or HTLV infection
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on days 0 and 14, cyclophosphamide IV on days 11 and 12, and aldesleukin SC BID for 14 days. Patients who have received radiation to the chest/lung tissue may receive gene-transduced T lymphocytes 90 days after completion of radiation.
    intervention Names
    1. Biological: Aldesleukin
    2. Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
    3. Drug: Cyclophosphamide
    4. Other: Laboratory Biomarker Analysis
    label
    Arm I, Stage I (T lymphocytes, cyclophosphamide, IL-2)
    type
    EXPERIMENTAL
  2. description
    Patients receive cyclophosphamide IV on days -3 and -2, autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on day 0, and aldesleukin SC BID for 14 days.
    intervention Names
    1. Biological: Aldesleukin
    2. Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
    3. Drug: Cyclophosphamide
    4. Other: Laboratory Biomarker Analysis
    label
    Arm I, Stage II (T lymphocytes, cyclophosphamide, IL-2)
    type
    EXPERIMENTAL
  3. description
    Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV between 24-96 hours after the last dose of chemotherapy and receive aldesleukin SC BID for 14 days. Patients then undergo surgery within 3-4 weeks after the T-cell infusion.
    intervention Names
    1. Biological: Aldesleukin
    2. Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
    3. Other: Laboratory Biomarker Analysis
    4. Procedure: Therapeutic Conventional Surgery
    label
    Arm II (T lymphocytes, IL-2, surgery)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm I, Stage I (T lymphocytes, cyclophosphamide, IL-2)
    2. Arm I, Stage II (T lymphocytes, cyclophosphamide, IL-2)
    3. Arm II (T lymphocytes, IL-2, surgery)
    description
    Given SC
    name
    Aldesleukin
    other Names
    1. 125-L-Serine-2-133-interleukin 2
    2. Proleukin
    3. r-serHuIL-2
    4. Recombinant Human IL-2
    5. Recombinant Human Interleukin-2
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Arm I, Stage I (T lymphocytes, cyclophosphamide, IL-2)
    2. Arm I, Stage II (T lymphocytes, cyclophosphamide, IL-2)
    3. Arm II (T lymphocytes, IL-2, surgery)
    description
    Given IV
    name
    Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
    type
    BIOLOGICAL
  3. arm Group Labels
    1. Arm I, Stage I (T lymphocytes, cyclophosphamide, IL-2)
    2. Arm I, Stage II (T lymphocytes, cyclophosphamide, IL-2)
    description
    Given IV
    name
    Cyclophosphamide
    other Names
    1. (-)-Cyclophosphamide
    2. 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
    3. Carloxan
    4. Ciclofosfamida
    5. Ciclofosfamide
    6. Cicloxal
    7. Clafen
    8. Claphene
    9. CP monohydrate
    10. CTX
    11. CYCLO-cell
    12. Cycloblastin
    type
    DRUG
  4. arm Group Labels
    1. Arm I, Stage I (T lymphocytes, cyclophosphamide, IL-2)
    2. Arm I, Stage II (T lymphocytes, cyclophosphamide, IL-2)
    3. Arm II (T lymphocytes, IL-2, surgery)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  5. arm Group Labels
    1. Arm II (T lymphocytes, IL-2, surgery)
    description
    Undergo surgical resection
    name
    Therapeutic Conventional Surgery
    type
    PROCEDURE
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
11
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. description
    Frequency of transferred T cells at biopsied tumor sites between the Tn and Tcm groups will be assessed.
    measure
    Frequency of Transferred T Cells at Biopsied Tumor Sites Between the T Cell (Tn) and Memory T Cell (Tcm) Groups
    time Frame
    Up to 15 years
  2. description
    Tetramer+ cells from peripheral blood, if detectable and available in sufficient number, evaluated for production of intracellular cytokines including interferon-gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), and IL-2. Intranuclear Ki-67 expression assessed on recovered tetramer+ T cells. Based on available numbers, ex vivo proliferative capacity after infusion assessed by labeling cells with carboxyfluorescein succinimidyl ester dye and measuring dilution in response to peptide stimulation. Phenotype of tetramer+ antigen-specific cells assessed using established immunophenotyping
    measure
    Functional Capacity of Transferred Cells, Measured by Production of Intracellular Cytokines
    time Frame
    Up to 15 years
  3. description
    The potential efficacy of the infused cells will be assessed and the substrate cell (TN or TCM) that is most effective based on the TTP of patients who have persisting TN cells to that of patients who have persisting TCM cells 3 months after the last infusion will be determined.
    measure
    Time to Progression (TTP) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria and RECIST 1.1 Mesothelioma Modified
    time Frame
    3 months after last infusion
primary Outcomes
  1. description
    Based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
    measure
    Number of Participants With Adverse Events
    time Frame
    Up to 6 months after the first T cell infusion
  2. description
    There were products generated for 11 participants and 10 participants were treated on the study. 8 participants received an infusion with Tn and Tcm cells. 1 participant received infusions with only Tn cells. 1 participant received their last infusion with only Tcm cells. The one participant that was not treated did successfully have Tn and Tcm cells generated but they were not treated due to their condition worsening.
    measure
    Count of Patients for Which T Cells Are Successfully Generated and Infused and Whether Only TN or TCM Could be Generated
    time Frame
    Up to 4 weeks
  3. description
    In vivo persistence of cells generated from the TN subset with cells generated from the TCM subset will be directly compared within each patient by high throughput T-cell receptor (TCR) beta sequencing. The one-sample T test will be used to assess the difference in mean persistence between groups, in which the outcome for each patient is the time to disappearance of infused cytotoxic T lymphocytes.
    measure
    Persistence of Transduced T Cells
    time Frame
    Up to 100 days after the last T cell infusion
Full study description
brief Summary
This phase I/II trial studies the side effects and best dose of genetically modified T cells in treating patients with stage III-IV non-small cell lung cancer (NSCLC) or mesothelioma. Many types of cancer cells, including NSCLC and mesothelioma, but not most normal cells, have a protein called Wilms tumor (WT)1 on their surfaces. This study takes a type of immune cell from patients, called T cells, and modifies their genes in the laboratory so that they are programmed to find cells with WT1 and kill them. The T cells are then given back to the patient. Cyclophosphamide and aldesleukin may also stimulate the immune system to attack cancer cells. Giving cyclophosphamide and aldesleukin with laboratory-treated T cells may help the body build an immune response to kill tumor cells.
detailed Description
PRIMARY OBJECTIVES: I. Determine the safety, and potential toxicities associated with treating patients with metastatic NSCLC and mesothelioma with polyclonal autologous central memory and naive cluster of differentiation (CD)8+ T cells that have been transduced to express a WT1-specific T-cell receptor (TCR) (Arm 1 and Arm 2). II. Determine the feasibility of treating patients with metastatic NSCLC and mesothelioma with polyclonal autologous central memory and naive CD8+ T cells that have been transduced to express a WT1-specific TCR (Arm 1 and Arm 2). III. Determine and compare the in vivo persistence in blood and tumor of transferred polyclonal autologous central memory and naive CD8+ T cells that have been transduced to express a WT1-specific TCR (Arm 1 and Arm 2). EXPLORATORY OBJECTIVES: I. Determine the antitumor efficacy for patients with metastatic NSCLC and mesothelioma (Arm 1), as measured by time to progression (TTP) based on the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. II. Determine the in vivo functional capacity of adoptively transferred polyclonal autologous CD8+ T cells that have been transduced to express a WT1-specific TCR, and assess the acquisition of phenotypic characteristics associated with T cell exhaustion (Arm 1 and Arm 2). III. Determine the migration to tumor sites of adoptively transferred polyclonal autologous CD8+ T cells that have been transduced to express a WT1-specific TCR (Arm 2). IV. Evaluate the tumor response and T cell infiltration in tumors of patients with stage IIIA NSCLC treated in the neo-adjuvant setting. OUTLINE: This is a phase I, dose-escalation study of autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes followed by a phase II study. Patients are assigned to 1 of 3 treatment arms. ARM I, STAGE I: Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes intravenously (IV) on days 0 and 14, cyclophosphamide IV on days 11 and 12, and aldesleukin (IL-2) subcutaneously (SC) twice daily (BID) for 14 days. Patients who have received radiation to the chest/lung tissue may receive T lymphocytes 90 days after completion of radiation. ARM I, STAGE II: Patients receive cyclophosphamide IV on days -3 and -2, autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on day 0, and aldesleukin SC BID for 14 days. ARM II: Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV between 24-96 hours after the last dose of chemotherapy and receive aldesleukin SC BID for 14 days. Patients then undergo surgery within 3-4 weeks after the T-cell infusion. After completion of study treatment, patients are followed up at 3, 6, and 12 months and then annually for 14 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-7ded12caaf67965bb84d
      requested nct id
      NCT02408016
      primary nct id
      NCT02408016
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
      payload sha256
      11ba3a66868d6c014ae8dd9a8a482c4494ef5ec721ab480584f2c8cbab6e0fe1
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-7ded12caaf67965bb84d
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02408016
      occurrences
      1. context exact
        NCT02408016
        end
        11
        exact text
        NCT02408016
        start
        0
      offset unit
      unicode_code_points
      query cond
      Malignant Mesothelioma
      query disease state id
      ds-malignant-mesothelioma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-malignant-mesothelioma-000.json
      source file sha256
      0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
      source json pointer
      /studies/82/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      ae8beda6b20933d39885d70f0894b3243d0fff1146051e0ef5fe2d488567ea98

    Preserved source evidence · Not medical advice